1.40
-0.04(-2.78%)
Currency In USD
| Previous Close | 1.44 |
| Open | 1.39 |
| Day High | 1.48 |
| Day Low | 1.39 |
| 52-Week High | 1.84 |
| 52-Week Low | 0.81 |
| Volume | 666,909 |
| Average Volume | 1.16M |
| Market Cap | 74.19M |
| PE | -0.9 |
| EPS | -1.56 |
| Moving Average 50 Days | 1.41 |
| Moving Average 200 Days | 1.25 |
| Change | -0.04 |
If you invested $1000 in PMV Pharmaceuticals, Inc. (PMVP) since IPO date, it would be worth $37.32 as of October 19, 2025 at a share price of $1.4. Whereas If you bought $1000 worth of PMV Pharmaceuticals, Inc. (PMVP) shares 3 years ago, it would be worth $115.7 as of October 19, 2025 at a share price of $1.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:01 PM GMT
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N.J., Oct. 1
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma33% overall response rate (ORR)
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 11, 2025 1:00 PM GMT
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David